CD36 and diffuse large B-cell lymphoma: This suggests that CD36 and CD37 may play a critical role in shaping the immune landscape of DLBCL and could serve as potential biomarkers for disease progression and response to treatment and appealing targets for novel therapeutic strategies in lymphoma [20,55,56,57].